Marc Beer Renovia

Marc Beer established Renovia Inc serving as the president as of today. Beer undertook his studies at the University of Miami and graduated with the bachelor’s degree in Business and Science. As a hardworking and determined individual, Beer works himself up tirelessly through various leadership positions to the current rank. The leader is a philanthropist who helps other people through their difficult life situations. Also, Beer offers his professional business advice to Miami University and serves as a strategic consultant in ova Science. Much of his money, resources, and time get used in bettering the living standards of the community. Beer is the principal promoter and co-founder of the committee for compensation and audit committee for Minerva Neurosciences.

 

Mark Beer received $32 million donations in round B series and $10 million venture debt to promote the development of Renovia. Beer is an expert in the utilization of advanced medical technology, like operating pharmaceutical devices that helps him to perform various diagnostics. The whole life of Beer, he dedicates to find the cure, diagnose, and prevent urinary incontinence in women. Today, more than 500 women live with the condition in the world.

 

Within this year, the food and drug administrators approved the use of the first Renovia product known as Leva. Also, Renovia receives various supports from many other companies, like the Longwood fund purposed to promote the healthcare sectors through donations in fighting healthcare issues. Renovia has other supporters, like the advisors from New York and Ascension Ventures from Missouri. Renovia is making all efforts to set safer grounds to do tests and launch the rest of its four products. Soon enough, Beer intends to come up with a new type of Leva.

 

Mark Beer realizes that all his efforts could not come true if not for the support from various organizations and the Renovia family. Therefore, the individual appreciates everyone who takes part in helping Beer to fulfill his endeavor. The principal focus of Beer is to come up with advanced diagnostic procedures and treatment processes that will help the women to get rid of the pelvic condition.

 

It is only with a clear understanding of the pelvic condition that can help one to come up with a long-term solution. Renovia determines to employ all types of treatment methods to promote pelvic health in women in the entire world. The institution uses the unique and strategic method of treatment, like patient-based app technology, advanced drug administration, and accurate data management.

 

When he finished school, Marc Beer joined hands with various healthcare institutions to help make the world a better place to live. Beer ensures all patients receive the right treatment procedure, and he addresses the health issues effective immediately. The individual focuses on creating consistency in commitment to serving the world. Learn more: https://www.crunchbase.com/person/marc-beer

Scott Rocklage Impact In The World Of Science

The disease of muscular dystrophy is beginning to lose the battle against modern medical research thanks in a big part to Scott Rocklage, PhD, who is the managing partner of 5AM Ventures. A leading venture capital company for the healthcare industry’s research, technology and drug development efforts.

 

Scott Rocklage became a venture partner with 5AM Ventures in 2003, in 2004 he was appointed the managing partner and has maintained that position with immense success ever since. His latest endeavors include teaming up with other venture capitalist in the healthcare industry to tackle Myotonic dystrophy I (DM1) which is the primary cause of adult muscular dystrophy. All of the venture capital companies combined have recently added $55.3 million dollars to the fight.

 

The lab soldiers in the fight are being lead by Expansion Therapeutics, a drug research and development company who’s recent findings have uncovered that symptoms of the chronic disease appear when toxic levels of RNA are reached. RNA molecular transfer from a patient’s DNA is converted to proteins and reaches a toxic level then Myotonic dystrophy I sets in. Causing major nervous system and other systems in the body to break down and become defective.

 

Lead by research from the lab of Matthew D Disney, PhD. Expansion Therapeutics is developing small molecule medications to fight the disease related RNA to arrest the growth of toxic levels. Learn more: http://www.rennovia.com/team/scott-m-rocklage/

 

Currently RNA triggered disease such as myotonic dystrophy at the time have no way of being treated but this is a huge step toward overcoming that challenge and the entire Expansion Therapeutics team is determined to give both hope and treatment to those patients who have neither right now. In addition to treating toxic RNA levels with small molecule medications the research team is at the same time working to develop medicines and treatments for patients that have direct medical needs as well.

 

The optimism and hope the researchers are expressing can be reinforced by the fact that they have Scott Rocklage in their corner for this fight. He has been responsible for getting approval for the innovative medications Teslascan, Omniscan and Cubicin from the FDA as well as being the inventor or co-inventor of 30 United States Patents. He began his education at Cal Berkeley with a major in Chemistry and then went on to receive his PhD. in the same major at M.I.T.

 

Rocklage can be found operating the 5AM Ventures main office in Boston these days.